Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 26K
2: EX-99.1 Miscellaneous Exhibit HTML 47K
7: R1 Cover HTML 46K
9: XML IDEA XML File -- Filing Summary XML 11K
6: XML XBRL Instance -- blue-20210519_htm XML 21K
8: EXCEL IDEA Workbook of Financial Reports XLSX 6K
4: EX-101.LAB XBRL Labels -- blue-20210519_lab XML 67K
5: EX-101.PRE XBRL Presentations -- blue-20210519_pre XML 33K
3: EX-101.SCH XBRL Schema -- blue-20210519 XSD 10K
10: JSON XBRL Instance as JSON Data -- MetaLinks 12± 17K
11: ZIP XBRL Zipped Folder -- 0001293971-21-000043-xbrl Zip 22K
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
i☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
iCommon
Stock, $0.01 par value per share
iBLUE
iThe NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Item 8.01Other Events.
On May 19, 2021, bluebird bio, Inc. (“bluebird”) and Bristol Myers Squibb Company issued a press release announcing new data and analyses from the pivotal
KarMMa study evaluating Abecma (idecabtagene vicleucel). This data will be presented at the American Society of Clinical Oncology (ASCO) 2021 Virtual Annual Meeting on June 4, 2021.
Cover Page Interactive
Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
